SHANGHAI, April 17, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2012 after the New York Stock Exchange closes on Thursday, May 10, 2012 (which will be Friday morning, May 11, 2012 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm ( Beijing/ Shanghai/ Hong Kong) on Friday, May 11, 2012, to discuss the first-quarter 2012 financial results and recent business activities. The conference call may be accessed by calling:
United States: 1-866-519-4004China (Landline): 800-819-0121China (Mobile): 400-620-8038 Hong Kong: 800-930-346 United Kingdom: 0-808-234-6646International: +65-6723-9381Conference ID : 70558333
A telephone replay will be available two hours after the call's completion at:United States: 1-866-214-5335China North: 10-800-714-0386 China South: 10-800-140-0386 Hong Kong: 800-901-596 United Kingdom: 0-800-731-7846International: +61-2-8235-5000Conference ID: 70558333 A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/. About WuXi PharmaTech WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please contact:
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts